GSK and S&P 500 Performance During 2007-08 Crisis. GSK stock declined from $53 in September 2007 (pre-crisis peak) to around $28 in March 2009, as the markets bottomed out, implying it lost 48% of ...

In the latest market close, GSK (GSK) reached $41.90, with a -1.04% movement compared to the previous day. The stock fell short of the S&P 500, which registered a gain of 0.52% for the day. Elsewhere, ...

GSK (GSK) closed at $37.56 in the latest trading session, marking a +0.59% move from the prior day. The stock outperformed the S&P 500, which registered a daily gain of 0.43%.

GSK is demonstrating strong operating performance and expects record sales for Shingrix this year. See why I rate GSK stock a strong buy. ... the stock has seen an 18% decline over the past ...

GSK (GSK) stock fell after reporting a 2% YoY revenue decline in Q2 2024, driven by an 18% YoY drop in vaccine sales. Read more here.

In other recent news, GlaxoSmithKline PLC (GSK) has reported a substantial performance in its third-quarter earnings call, with a 9% sales growth and a 19% profit growth year-to-date.

GSK Q1 Earnings Beat, Sales Lag, Stock Gains on Tariff Reassurance. 1w. GSK plc GSK reported first-quarter 2025 core earnings of $1.13 per American ... driven by strong performance across all ...

GSK GSK stock has risen 21.5% in the past six months. ... the company expects sales in the Vaccines segment to decline by a low single-digit percentage at CER. GSK’s Price Performance, ...

GSK GSK stock has risen 21.5% in the past six months. The consistently strong performance of the Specialty Medicines unit, regulatory and pipeline successes and an optimistic outlook for the long ...